SYNTHESIS OF 2-(4-AMINOPHENYL) BENZOTHIAZOLE DERIVATIVES AND USE THEREOF
申请人:Wang Jeh-Jeng
公开号:US20120215154A1
公开(公告)日:2012-08-23
The present invention provides a method of preparing a compound of formula 6
comprising:
(a) reacting a compound of formula 1
with a compound of formula 2
to form a compound of formula 3
wherein X of formula 2 is Cl or OH;
(b) treating the compound formula 3 with Lawesson's reagent to form a compound of formula 4
(c) reacting a compound of formula 4 with potassium ferricyanide to produce a compound of formula 5
and
(d) performing catalytic reduction of nitro group of the compound of formula 5 with palladium on charcoal to generate the compound of formula 6,
wherein R
1
of formulae 1-6 is H, C
1-10
alkyl, C
1-10
alkoxy or C
1-10
haloalkyl, and R
2
of formulae 1-6 is H or C
1-10
alkyl.
The present invention also provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R
1
and R
2
are defined as the above) in a pharmaceutically acceptable carrier to the patient; waiting for a sufficient time to allow the administered compound to be taken up by a target tissue having the at least one tumor; and irradiating a region of the patient containing the target tissue; wherein growth of the tumor is inhibited.
Photodynamic therapy (PDT) employing exogenous photosensitizers is currently being approved for treatment of basal cell carcinoma (BCC). 2-(4-Aminophenyl)benzothiazoles (6) consist of chromophoric structure and absorb light in the UVA (315–400 nm). These results encouraged us to design and synthesize a diversity of 2-phenylbenzothiazoles (6). Studies on the apoptotic mechanism involved in photosensitive effects
SYNTHESIS OF 2-(4-AMINOPHENYL)BENZOTHIAZOLE DERIVATIVES AND USE THEREOF
申请人:KAOHSIUNG MEDICAL UNIVERSITY
公开号:US20140046290A1
公开(公告)日:2014-02-13
The present invention provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R
1
and R
2
are defined as the above) in a pharmaceutically acceptable carrier to the patient; waiting for a sufficient time to allow the administered compound to be taken up by a target tissue having the at least one tumor; and irradiating a region of the patient containing the target tissue, wherein growth of the tumor is inhibited.